Natalie Serkova
Concepts (694)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Spectroscopy | 36 | 2014 | 537 | 2.940 |
Why?
| Cyclosporine | 20 | 2012 | 263 | 2.660 |
Why?
| Immunosuppressive Agents | 23 | 2013 | 854 | 2.180 |
Why?
| Sirolimus | 17 | 2013 | 266 | 1.780 |
Why?
| Magnetic Resonance Imaging | 25 | 2024 | 3386 | 1.730 |
Why?
| Pyrimidines | 8 | 2017 | 458 | 1.250 |
Why?
| Piperazines | 6 | 2009 | 340 | 1.250 |
Why?
| Metabolomics | 11 | 2021 | 652 | 1.170 |
Why?
| Energy Metabolism | 14 | 2019 | 873 | 1.140 |
Why?
| Glucose | 14 | 2021 | 1000 | 1.120 |
Why?
| Contrast Media | 6 | 2017 | 393 | 1.090 |
Why?
| Antineoplastic Agents | 15 | 2022 | 2045 | 1.050 |
Why?
| Brain | 14 | 2024 | 2668 | 1.040 |
Why?
| Liver | 12 | 2020 | 1839 | 0.930 |
Why?
| Neoplasms | 14 | 2017 | 2442 | 0.910 |
Why?
| Animals | 101 | 2025 | 35286 | 0.910 |
Why?
| Biomarkers | 14 | 2019 | 3963 | 0.910 |
Why?
| Drug Resistance, Neoplasm | 6 | 2017 | 751 | 0.880 |
Why?
| Neoplasms, Experimental | 3 | 2020 | 170 | 0.840 |
Why?
| Reperfusion Injury | 11 | 2014 | 271 | 0.730 |
Why?
| Biomarkers, Tumor | 10 | 2020 | 1161 | 0.680 |
Why?
| Rats | 31 | 2015 | 5479 | 0.680 |
Why?
| Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 21 | 0.660 |
Why?
| Multimodal Imaging | 1 | 2020 | 110 | 0.660 |
Why?
| Protein Kinase Inhibitors | 10 | 2018 | 885 | 0.650 |
Why?
| Cell Line, Tumor | 27 | 2025 | 3186 | 0.650 |
Why?
| Ferrosoferric Oxide | 3 | 2019 | 26 | 0.620 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 118 | 0.610 |
Why?
| Nanoparticles | 5 | 2024 | 374 | 0.610 |
Why?
| Metabolome | 5 | 2019 | 338 | 0.600 |
Why?
| Ischemic Preconditioning | 2 | 2009 | 40 | 0.560 |
Why?
| Mice | 49 | 2025 | 16905 | 0.540 |
Why?
| Fusion Proteins, bcr-abl | 5 | 2015 | 69 | 0.510 |
Why?
| Phospholipids | 7 | 2010 | 215 | 0.510 |
Why?
| Hypoxia | 6 | 2015 | 1084 | 0.490 |
Why?
| Aging | 5 | 2020 | 1774 | 0.490 |
Why?
| Everolimus | 12 | 2013 | 87 | 0.490 |
Why?
| Rats, Wistar | 11 | 2010 | 441 | 0.480 |
Why?
| Body Fluids | 5 | 2019 | 63 | 0.470 |
Why?
| Glutathione | 9 | 2023 | 347 | 0.470 |
Why?
| Inositol | 4 | 2021 | 26 | 0.460 |
Why?
| Glutamine | 6 | 2013 | 99 | 0.460 |
Why?
| Epilepsy, Post-Traumatic | 1 | 2013 | 3 | 0.440 |
Why?
| Brain Injuries | 3 | 2014 | 466 | 0.440 |
Why?
| Organ Specificity | 4 | 2013 | 295 | 0.430 |
Why?
| Positron-Emission Tomography | 10 | 2020 | 279 | 0.430 |
Why?
| Nephritis | 1 | 2013 | 22 | 0.430 |
Why?
| Apoptosis | 15 | 2024 | 2491 | 0.430 |
Why?
| Lupus Nephritis | 2 | 2011 | 49 | 0.420 |
Why?
| Mitochondria | 7 | 2014 | 876 | 0.410 |
Why?
| Glioma | 4 | 2024 | 347 | 0.410 |
Why?
| Imatinib Mesylate | 7 | 2014 | 75 | 0.400 |
Why?
| Brain Neoplasms | 6 | 2025 | 1143 | 0.400 |
Why?
| Rhabdoid Tumor | 2 | 2025 | 95 | 0.390 |
Why?
| Leukemia | 2 | 2018 | 229 | 0.390 |
Why?
| Blood-Brain Barrier | 3 | 2024 | 131 | 0.390 |
Why?
| Humans | 75 | 2025 | 129143 | 0.390 |
Why?
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 1336 | 0.380 |
Why?
| Disease Models, Animal | 16 | 2023 | 4056 | 0.370 |
Why?
| Placenta | 3 | 2009 | 723 | 0.370 |
Why?
| Metabolism | 3 | 2017 | 38 | 0.370 |
Why?
| Infratentorial Neoplasms | 2 | 2024 | 55 | 0.370 |
Why?
| Oxidative Stress | 5 | 2010 | 1265 | 0.360 |
Why?
| Reactive Oxygen Species | 5 | 2013 | 593 | 0.360 |
Why?
| Time Factors | 12 | 2013 | 6541 | 0.360 |
Why?
| Drug Monitoring | 3 | 2013 | 215 | 0.360 |
Why?
| Myocardium | 3 | 2013 | 978 | 0.360 |
Why?
| Kidney | 7 | 2023 | 1384 | 0.350 |
Why?
| Benzamides | 6 | 2009 | 203 | 0.350 |
Why?
| Cerebellar Neoplasms | 2 | 2023 | 150 | 0.350 |
Why?
| Kidney Diseases | 2 | 2020 | 382 | 0.340 |
Why?
| Seizures | 1 | 2013 | 401 | 0.340 |
Why?
| Astrocytes | 4 | 2015 | 195 | 0.340 |
Why?
| Medulloblastoma | 2 | 2023 | 191 | 0.340 |
Why?
| Ependymoma | 2 | 2024 | 161 | 0.330 |
Why?
| Liver Diseases | 2 | 2010 | 290 | 0.330 |
Why?
| Xenograft Model Antitumor Assays | 10 | 2024 | 808 | 0.330 |
Why?
| Diagnostic Imaging | 2 | 2011 | 325 | 0.330 |
Why?
| Molecular Targeted Therapy | 2 | 2017 | 390 | 0.320 |
Why?
| Cell Proliferation | 13 | 2022 | 2368 | 0.320 |
Why?
| Molecular Probes | 1 | 2009 | 36 | 0.320 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 274 | 0.320 |
Why?
| Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.310 |
Why?
| Liver Transplantation | 2 | 2007 | 831 | 0.310 |
Why?
| Silymarin | 4 | 2016 | 199 | 0.300 |
Why?
| Lactic Acid | 7 | 2013 | 298 | 0.300 |
Why?
| Prostatic Neoplasms | 5 | 2016 | 996 | 0.300 |
Why?
| Complement C3b | 2 | 2023 | 32 | 0.300 |
Why?
| Spermine | 1 | 2008 | 28 | 0.300 |
Why?
| Citric Acid | 1 | 2008 | 30 | 0.290 |
Why?
| K562 Cells | 4 | 2009 | 85 | 0.290 |
Why?
| Adaptation, Physiological | 2 | 2009 | 513 | 0.290 |
Why?
| Adenosine Triphosphate | 6 | 2009 | 478 | 0.290 |
Why?
| Hibernation | 2 | 2014 | 74 | 0.290 |
Why?
| Drug Design | 2 | 2007 | 156 | 0.280 |
Why?
| Tomography, X-Ray Computed | 3 | 2020 | 2511 | 0.280 |
Why?
| Graft Rejection | 5 | 2010 | 598 | 0.280 |
Why?
| Kidney Transplantation | 4 | 2010 | 670 | 0.270 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 542 | 0.270 |
Why?
| Creatine | 3 | 2021 | 58 | 0.270 |
Why?
| Prostate | 1 | 2008 | 173 | 0.270 |
Why?
| Male | 47 | 2024 | 63455 | 0.260 |
Why?
| Altitude | 3 | 2009 | 462 | 0.260 |
Why?
| Choline | 2 | 2009 | 123 | 0.260 |
Why?
| Rats, Sprague-Dawley | 11 | 2015 | 2395 | 0.260 |
Why?
| Liver Failure | 1 | 2007 | 91 | 0.260 |
Why?
| Pneumonia | 2 | 2011 | 616 | 0.260 |
Why?
| Colorectal Neoplasms | 4 | 2018 | 748 | 0.250 |
Why?
| Drug Therapy | 1 | 2006 | 80 | 0.250 |
Why?
| Nanomedicine | 2 | 2024 | 32 | 0.250 |
Why?
| Dietary Supplements | 3 | 2023 | 534 | 0.250 |
Why?
| Interleukin-1beta | 1 | 2008 | 372 | 0.250 |
Why?
| Signal Transduction | 11 | 2019 | 4919 | 0.250 |
Why?
| Brain Injuries, Traumatic | 2 | 2023 | 341 | 0.250 |
Why?
| Myocardial Reperfusion Injury | 2 | 2003 | 129 | 0.250 |
Why?
| Sex Characteristics | 1 | 2010 | 736 | 0.240 |
Why?
| Blotting, Western | 6 | 2019 | 1202 | 0.240 |
Why?
| fms-Like Tyrosine Kinase 3 | 2 | 2016 | 46 | 0.240 |
Why?
| Sirtuin 2 | 1 | 2025 | 24 | 0.240 |
Why?
| Neovascularization, Pathologic | 4 | 2018 | 295 | 0.240 |
Why?
| SMARCB1 Protein | 1 | 2025 | 29 | 0.240 |
Why?
| Macrolides | 2 | 2013 | 60 | 0.230 |
Why?
| Protein Kinases | 2 | 2004 | 318 | 0.230 |
Why?
| Drug Interactions | 6 | 2012 | 393 | 0.230 |
Why?
| Protein-Tyrosine Kinases | 3 | 2014 | 431 | 0.230 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2022 | 507 | 0.220 |
Why?
| Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| Sepsis | 4 | 2013 | 572 | 0.220 |
Why?
| Neurotoxicity Syndromes | 1 | 2004 | 23 | 0.220 |
Why?
| Microbubbles | 1 | 2024 | 48 | 0.220 |
Why?
| Obesity | 3 | 2006 | 2879 | 0.220 |
Why?
| Carcinoma, Hepatocellular | 2 | 2020 | 272 | 0.220 |
Why?
| Dose-Response Relationship, Drug | 10 | 2012 | 2008 | 0.220 |
Why?
| Cell Transformation, Neoplastic | 3 | 2015 | 326 | 0.220 |
Why?
| Organ Transplantation | 2 | 2004 | 228 | 0.220 |
Why?
| Chromatography, High Pressure Liquid | 5 | 2009 | 580 | 0.210 |
Why?
| Glycolysis | 4 | 2010 | 311 | 0.210 |
Why?
| Autophagy | 2 | 2018 | 266 | 0.210 |
Why?
| DNA Repair | 2 | 2024 | 206 | 0.210 |
Why?
| Autolysis | 1 | 2003 | 3 | 0.210 |
Why?
| Lung Transplantation | 3 | 2000 | 289 | 0.210 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2008 | 1201 | 0.200 |
Why?
| Fatty Liver | 1 | 2005 | 230 | 0.200 |
Why?
| Glomerulonephritis | 1 | 2023 | 46 | 0.200 |
Why?
| Deoxycytidine | 2 | 2017 | 164 | 0.200 |
Why?
| Phosphates | 2 | 2001 | 179 | 0.200 |
Why?
| In Vitro Techniques | 5 | 2016 | 1085 | 0.190 |
Why?
| Colonic Neoplasms | 3 | 2013 | 241 | 0.190 |
Why?
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 187 | 0.190 |
Why?
| Specimen Handling | 1 | 2003 | 162 | 0.190 |
Why?
| Carbon Isotopes | 3 | 2009 | 126 | 0.190 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 64 | 0.190 |
Why?
| Mice, Nude | 8 | 2016 | 682 | 0.180 |
Why?
| Chemoradiotherapy | 2 | 2019 | 208 | 0.180 |
Why?
| Radiation Tolerance | 1 | 2022 | 98 | 0.180 |
Why?
| Image Processing, Computer-Assisted | 3 | 2019 | 740 | 0.180 |
Why?
| Tendinopathy | 1 | 2021 | 22 | 0.180 |
Why?
| Hydroxamic Acids | 2 | 2011 | 88 | 0.180 |
Why?
| Photoacoustic Techniques | 1 | 2020 | 5 | 0.180 |
Why?
| Lung | 8 | 2018 | 3926 | 0.180 |
Why?
| Gene Expression Regulation | 4 | 2019 | 2536 | 0.180 |
Why?
| Magnetite Nanoparticles | 2 | 2011 | 29 | 0.180 |
Why?
| Anterior Cruciate Ligament Injuries | 1 | 2022 | 140 | 0.170 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 77 | 0.170 |
Why?
| TOR Serine-Threonine Kinases | 5 | 2018 | 395 | 0.170 |
Why?
| Anticarcinogenic Agents | 2 | 2011 | 77 | 0.170 |
Why?
| Osteoarthritis | 1 | 2022 | 168 | 0.170 |
Why?
| Insulin Resistance | 2 | 2019 | 1165 | 0.170 |
Why?
| Heat-Shock Proteins | 3 | 2006 | 136 | 0.170 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2020 | 48 | 0.170 |
Why?
| Mass Spectrometry | 4 | 2011 | 713 | 0.170 |
Why?
| Mammary Glands, Animal | 2 | 2014 | 120 | 0.170 |
Why?
| Camptothecin | 2 | 2013 | 110 | 0.170 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.170 |
Why?
| Particle Accelerators | 1 | 2019 | 10 | 0.170 |
Why?
| Electromagnetic Phenomena | 1 | 2019 | 22 | 0.160 |
Why?
| Perfusion | 3 | 2009 | 197 | 0.160 |
Why?
| Scavenger Receptors, Class A | 1 | 2019 | 12 | 0.160 |
Why?
| Heart | 1 | 2003 | 637 | 0.160 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2011 | 209 | 0.160 |
Why?
| Lactation | 2 | 2014 | 169 | 0.160 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2019 | 69 | 0.160 |
Why?
| Complement Factor H | 1 | 2020 | 72 | 0.160 |
Why?
| Inflammation | 4 | 2024 | 2735 | 0.160 |
Why?
| Brain Chemistry | 1 | 2000 | 118 | 0.160 |
Why?
| Fatty Acids | 2 | 2015 | 426 | 0.160 |
Why?
| Macrophages, Peritoneal | 1 | 2019 | 92 | 0.160 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1554 | 0.160 |
Why?
| Endoplasmic Reticulum Stress | 3 | 2014 | 101 | 0.160 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2021 | 126 | 0.160 |
Why?
| Precursor Cells, B-Lymphoid | 2 | 2017 | 38 | 0.160 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 131 | 0.160 |
Why?
| Receptor, EphB4 | 1 | 2019 | 36 | 0.150 |
Why?
| Ephrin-B2 | 1 | 2019 | 50 | 0.150 |
Why?
| Lipogenesis | 2 | 2016 | 59 | 0.150 |
Why?
| Angiogenesis Inhibitors | 2 | 2011 | 219 | 0.150 |
Why?
| Whey Proteins | 1 | 2018 | 4 | 0.150 |
Why?
| Neoplasm Proteins | 2 | 2020 | 419 | 0.150 |
Why?
| Phosphocreatine | 3 | 2004 | 43 | 0.150 |
Why?
| Smad4 Protein | 1 | 2018 | 38 | 0.150 |
Why?
| Glucose Clamp Technique | 1 | 2019 | 194 | 0.150 |
Why?
| Tumor Microenvironment | 2 | 2019 | 627 | 0.150 |
Why?
| Tracheal Stenosis | 1 | 2018 | 18 | 0.150 |
Why?
| Histones | 2 | 2020 | 588 | 0.150 |
Why?
| Salivary Gland Neoplasms | 1 | 2018 | 33 | 0.150 |
Why?
| Anilides | 1 | 2018 | 70 | 0.150 |
Why?
| Polyenes | 1 | 1997 | 16 | 0.140 |
Why?
| Acute Lung Injury | 2 | 2011 | 279 | 0.140 |
Why?
| Rats, Zucker | 3 | 2006 | 30 | 0.140 |
Why?
| Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 259 | 0.140 |
Why?
| Cells, Cultured | 6 | 2019 | 4075 | 0.140 |
Why?
| Mucin-1 | 1 | 2017 | 19 | 0.140 |
Why?
| Kinetics | 3 | 2009 | 1643 | 0.140 |
Why?
| Folic Acid Deficiency | 1 | 2017 | 48 | 0.140 |
Why?
| Female | 28 | 2022 | 68493 | 0.140 |
Why?
| Neuroprotective Agents | 1 | 2018 | 122 | 0.140 |
Why?
| Phosphorylation | 4 | 2013 | 1710 | 0.140 |
Why?
| Fibroblasts | 2 | 2016 | 947 | 0.140 |
Why?
| Liver Neoplasms | 2 | 2020 | 637 | 0.140 |
Why?
| PTEN Phosphohydrolase | 1 | 2018 | 161 | 0.140 |
Why?
| Lactates | 3 | 2006 | 85 | 0.130 |
Why?
| Drug Synergism | 5 | 2013 | 370 | 0.130 |
Why?
| Adenosine Diphosphate | 2 | 2009 | 80 | 0.130 |
Why?
| Macrophages | 3 | 2019 | 1481 | 0.130 |
Why?
| Pancreatic Neoplasms | 2 | 2017 | 879 | 0.130 |
Why?
| Quinazolines | 2 | 2008 | 243 | 0.130 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.130 |
Why?
| Tissue Extracts | 2 | 2009 | 19 | 0.130 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2016 | 50 | 0.130 |
Why?
| Heme Oxygenase (Decyclizing) | 2 | 2013 | 22 | 0.130 |
Why?
| Inflammation Mediators | 1 | 2019 | 504 | 0.130 |
Why?
| Hematopoiesis | 1 | 2017 | 183 | 0.130 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 84 | 0.130 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2016 | 56 | 0.130 |
Why?
| Transcription Factors | 5 | 2014 | 1644 | 0.130 |
Why?
| Folic Acid | 1 | 2017 | 184 | 0.130 |
Why?
| Blood Glucose | 4 | 2019 | 2098 | 0.130 |
Why?
| Alcohol Oxidoreductases | 1 | 2016 | 60 | 0.130 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 257 | 0.130 |
Why?
| Pyrazoles | 2 | 2010 | 404 | 0.130 |
Why?
| Drug Delivery Systems | 3 | 2024 | 332 | 0.130 |
Why?
| Creatinine | 4 | 2005 | 490 | 0.130 |
Why?
| Lipid Peroxidation | 3 | 2006 | 151 | 0.120 |
Why?
| Flow Cytometry | 2 | 2010 | 1155 | 0.120 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2016 | 199 | 0.120 |
Why?
| Fluorouracil | 2 | 2024 | 197 | 0.120 |
Why?
| Neuroglia | 1 | 1996 | 163 | 0.120 |
Why?
| Lipid Metabolism | 4 | 2019 | 497 | 0.120 |
Why?
| Radiography | 2 | 2008 | 794 | 0.120 |
Why?
| Hypothermia, Induced | 2 | 2006 | 76 | 0.120 |
Why?
| Brain Concussion | 1 | 2023 | 549 | 0.120 |
Why?
| Hernias, Diaphragmatic, Congenital | 1 | 2018 | 203 | 0.120 |
Why?
| Methylamines | 2 | 2005 | 30 | 0.120 |
Why?
| Paracrine Communication | 1 | 2015 | 61 | 0.120 |
Why?
| Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| Myocardial Infarction | 1 | 2002 | 1021 | 0.120 |
Why?
| Nuclear Proteins | 2 | 2023 | 658 | 0.120 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 432 | 0.120 |
Why?
| Homeostasis | 1 | 2018 | 605 | 0.120 |
Why?
| Fatty Acids, Unsaturated | 2 | 2005 | 97 | 0.120 |
Why?
| Pentacyclic Triterpenes | 1 | 2014 | 15 | 0.120 |
Why?
| Pyridines | 1 | 2018 | 478 | 0.120 |
Why?
| Indoles | 2 | 2015 | 383 | 0.110 |
Why?
| Models, Animal | 2 | 2009 | 376 | 0.110 |
Why?
| Treatment Outcome | 9 | 2024 | 10192 | 0.110 |
Why?
| Ferric Compounds | 1 | 2014 | 46 | 0.110 |
Why?
| ras Proteins | 2 | 2013 | 144 | 0.110 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.110 |
Why?
| Rats, Inbred Lew | 4 | 2010 | 111 | 0.110 |
Why?
| Hypertension, Pulmonary | 2 | 2016 | 1894 | 0.110 |
Why?
| Lipoxygenase Inhibitors | 1 | 2014 | 38 | 0.110 |
Why?
| Leukotrienes | 1 | 2014 | 37 | 0.110 |
Why?
| Convulsants | 1 | 2013 | 8 | 0.110 |
Why?
| Dextrans | 2 | 2014 | 83 | 0.110 |
Why?
| Kainic Acid | 1 | 2013 | 34 | 0.110 |
Why?
| NAD | 2 | 2004 | 75 | 0.110 |
Why?
| Propranolol | 1 | 2013 | 50 | 0.110 |
Why?
| Prognosis | 4 | 2017 | 3766 | 0.110 |
Why?
| Urothelium | 1 | 2013 | 37 | 0.110 |
Why?
| Brain Edema | 1 | 2013 | 60 | 0.110 |
Why?
| Azoxymethane | 1 | 2013 | 19 | 0.100 |
Why?
| Cell Survival | 4 | 2016 | 1074 | 0.100 |
Why?
| Unfolded Protein Response | 1 | 2013 | 53 | 0.100 |
Why?
| Mice, Inbred BALB C | 4 | 2019 | 1246 | 0.100 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 97 | 0.100 |
Why?
| Fetal Growth Retardation | 1 | 2019 | 550 | 0.100 |
Why?
| Grape Seed Extract | 1 | 2013 | 44 | 0.100 |
Why?
| Estrogens | 1 | 2015 | 346 | 0.100 |
Why?
| Equipment Design | 2 | 2019 | 512 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 946 | 0.100 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2015 | 193 | 0.100 |
Why?
| Phytic Acid | 1 | 2012 | 43 | 0.100 |
Why?
| Severity of Illness Index | 2 | 2013 | 2736 | 0.100 |
Why?
| Tumor Cells, Cultured | 3 | 2019 | 943 | 0.100 |
Why?
| Insulin | 3 | 2019 | 2325 | 0.100 |
Why?
| Pregnancy | 6 | 2019 | 6392 | 0.100 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 107 | 0.100 |
Why?
| Shock, Hemorrhagic | 1 | 2014 | 165 | 0.100 |
Why?
| Metabolic Diseases | 1 | 2013 | 104 | 0.100 |
Why?
| Image Enhancement | 2 | 2010 | 167 | 0.100 |
Why?
| Thiophenes | 1 | 2013 | 117 | 0.100 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 1445 | 0.100 |
Why?
| Reference Values | 3 | 2019 | 793 | 0.100 |
Why?
| Radionuclide Imaging | 1 | 2012 | 122 | 0.100 |
Why?
| Mice, Transgenic | 6 | 2015 | 2117 | 0.090 |
Why?
| Quinolines | 1 | 2013 | 156 | 0.090 |
Why?
| Feasibility Studies | 2 | 2019 | 865 | 0.090 |
Why?
| HSP70 Heat-Shock Proteins | 3 | 2010 | 69 | 0.090 |
Why?
| Proto-Oncogene Proteins | 2 | 2013 | 635 | 0.090 |
Why?
| Isotope Labeling | 1 | 2012 | 74 | 0.090 |
Why?
| Temperature | 3 | 2014 | 635 | 0.090 |
Why?
| Reproducibility of Results | 5 | 2019 | 3077 | 0.090 |
Why?
| Calcineurin | 1 | 2012 | 98 | 0.090 |
Why?
| Urinary Bladder | 1 | 2013 | 175 | 0.090 |
Why?
| Sarcoma | 1 | 2013 | 175 | 0.090 |
Why?
| Adrenergic beta-Antagonists | 1 | 2013 | 321 | 0.090 |
Why?
| Tissue Distribution | 2 | 2003 | 315 | 0.090 |
Why?
| Electroencephalography | 1 | 2013 | 399 | 0.090 |
Why?
| Mice, Inbred NOD | 3 | 2019 | 587 | 0.090 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 42 | 0.090 |
Why?
| Glioblastoma | 1 | 2014 | 322 | 0.090 |
Why?
| Antibodies, Monoclonal | 3 | 2023 | 1363 | 0.090 |
Why?
| Boronic Acids | 1 | 2011 | 37 | 0.090 |
Why?
| Models, Biological | 5 | 2013 | 1722 | 0.090 |
Why?
| Nucleotides | 2 | 2017 | 122 | 0.090 |
Why?
| Sciuridae | 2 | 2014 | 146 | 0.090 |
Why?
| Tandem Mass Spectrometry | 2 | 2014 | 522 | 0.090 |
Why?
| Adult | 10 | 2013 | 35469 | 0.090 |
Why?
| Tacrolimus | 1 | 2012 | 193 | 0.090 |
Why?
| Benzimidazoles | 1 | 2011 | 162 | 0.090 |
Why?
| Phosphatidylinositol 3-Kinases | 3 | 2018 | 360 | 0.090 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2010 | 171 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2011 | 106 | 0.090 |
Why?
| Hydroxybutyrates | 2 | 2010 | 14 | 0.080 |
Why?
| Complement C3-C5 Convertases | 1 | 2010 | 22 | 0.080 |
Why?
| Pyrazines | 1 | 2011 | 87 | 0.080 |
Why?
| Heart Ventricles | 1 | 2015 | 781 | 0.080 |
Why?
| Cricetulus | 1 | 2010 | 108 | 0.080 |
Why?
| CHO Cells | 1 | 2010 | 154 | 0.080 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2016 | 592 | 0.080 |
Why?
| Cognition Disorders | 1 | 2014 | 505 | 0.080 |
Why?
| Cricetinae | 1 | 2010 | 278 | 0.080 |
Why?
| Epigenomics | 2 | 2020 | 110 | 0.080 |
Why?
| Fatty Acids, Monounsaturated | 2 | 2010 | 52 | 0.080 |
Why?
| Mice, Knockout | 5 | 2020 | 2871 | 0.080 |
Why?
| TRPP Cation Channels | 1 | 2010 | 79 | 0.080 |
Why?
| Analysis of Variance | 2 | 2010 | 1288 | 0.080 |
Why?
| ErbB Receptors | 2 | 2015 | 602 | 0.080 |
Why?
| Ribose | 1 | 2009 | 22 | 0.080 |
Why?
| Neoplasm Transplantation | 3 | 2019 | 256 | 0.080 |
Why?
| Cysts | 1 | 2010 | 108 | 0.080 |
Why?
| Cell Extracts | 1 | 2009 | 17 | 0.080 |
Why?
| Dinoprost | 1 | 2009 | 44 | 0.080 |
Why?
| Deoxyglucose | 1 | 2009 | 52 | 0.080 |
Why?
| Intestine, Small | 1 | 2010 | 150 | 0.080 |
Why?
| RNA, Neoplasm | 1 | 2009 | 86 | 0.080 |
Why?
| Percussion | 1 | 2008 | 2 | 0.080 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 130 | 0.080 |
Why?
| History, 21st Century | 1 | 2009 | 183 | 0.080 |
Why?
| Surgical Equipment | 1 | 2008 | 13 | 0.080 |
Why?
| Mutation | 3 | 2020 | 3705 | 0.080 |
Why?
| Alanine | 2 | 2013 | 142 | 0.080 |
Why?
| Sulfonamides | 2 | 2011 | 495 | 0.080 |
Why?
| History, 20th Century | 1 | 2009 | 291 | 0.070 |
Why?
| Systems Biology | 1 | 2009 | 59 | 0.070 |
Why?
| Receptor, ErbB-3 | 1 | 2008 | 44 | 0.070 |
Why?
| Macaca fascicularis | 4 | 2000 | 62 | 0.070 |
Why?
| Complement C3d | 2 | 2023 | 65 | 0.070 |
Why?
| Oxygen | 2 | 2010 | 914 | 0.070 |
Why?
| Body Weight | 4 | 2012 | 939 | 0.070 |
Why?
| Neurons | 1 | 1996 | 1493 | 0.070 |
Why?
| Oxidation-Reduction | 3 | 2016 | 1028 | 0.070 |
Why?
| Critical Illness | 2 | 2011 | 757 | 0.070 |
Why?
| Protein Transport | 1 | 2009 | 428 | 0.070 |
Why?
| Area Under Curve | 1 | 2008 | 304 | 0.070 |
Why?
| Lymphocytes | 1 | 2009 | 378 | 0.070 |
Why?
| DNA | 2 | 2009 | 1396 | 0.070 |
Why?
| Triglycerides | 2 | 2010 | 527 | 0.070 |
Why?
| Disease Progression | 5 | 2018 | 2622 | 0.070 |
Why?
| Heart-Assist Devices | 1 | 2013 | 537 | 0.070 |
Why?
| Heterografts | 2 | 2019 | 133 | 0.070 |
Why?
| Oxidative Phosphorylation | 2 | 2005 | 187 | 0.070 |
Why?
| X-Ray Microtomography | 2 | 2021 | 83 | 0.070 |
Why?
| Tritium | 1 | 2006 | 75 | 0.070 |
Why?
| Age Factors | 2 | 2011 | 3140 | 0.070 |
Why?
| Chromatin | 2 | 2020 | 477 | 0.070 |
Why?
| Up-Regulation | 2 | 2006 | 838 | 0.070 |
Why?
| Mice, Inbred C57BL | 5 | 2018 | 5438 | 0.070 |
Why?
| ROC Curve | 1 | 2008 | 502 | 0.070 |
Why?
| MicroRNAs | 1 | 2013 | 676 | 0.070 |
Why?
| Medical Oncology | 1 | 2009 | 268 | 0.060 |
Why?
| Body Temperature | 1 | 2007 | 212 | 0.060 |
Why?
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 254 | 0.060 |
Why?
| Leukocytes, Mononuclear | 1 | 2009 | 545 | 0.060 |
Why?
| Maximum Tolerated Dose | 3 | 2013 | 193 | 0.060 |
Why?
| Receptor, ErbB-2 | 1 | 2008 | 325 | 0.060 |
Why?
| Nitrogen | 1 | 2007 | 162 | 0.060 |
Why?
| Heat-Shock Response | 1 | 2006 | 72 | 0.060 |
Why?
| Piperidines | 1 | 2007 | 198 | 0.060 |
Why?
| Liver Failure, Acute | 1 | 2006 | 64 | 0.060 |
Why?
| Survival Rate | 3 | 2019 | 1869 | 0.060 |
Why?
| Cell Differentiation | 2 | 2025 | 1888 | 0.060 |
Why?
| Deuterium | 1 | 2005 | 87 | 0.060 |
Why?
| Lung Injury | 1 | 2008 | 210 | 0.060 |
Why?
| Allantoin | 1 | 2005 | 2 | 0.060 |
Why?
| Alcohol Drinking | 1 | 2012 | 763 | 0.060 |
Why?
| Betaine | 1 | 2005 | 75 | 0.060 |
Why?
| Glutamic Acid | 2 | 2010 | 234 | 0.060 |
Why?
| Methionine | 1 | 2005 | 155 | 0.060 |
Why?
| Seasons | 1 | 2007 | 494 | 0.060 |
Why?
| Reference Standards | 2 | 2019 | 176 | 0.060 |
Why?
| Glutamates | 1 | 2004 | 57 | 0.060 |
Why?
| Lipids | 2 | 2021 | 625 | 0.060 |
Why?
| Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.060 |
Why?
| Heart Rate | 2 | 2009 | 802 | 0.050 |
Why?
| Free Radical Scavengers | 1 | 2004 | 82 | 0.050 |
Why?
| Hot Temperature | 1 | 2006 | 368 | 0.050 |
Why?
| Dacarbazine | 2 | 2014 | 93 | 0.050 |
Why?
| Aged | 5 | 2013 | 21996 | 0.050 |
Why?
| Gene Expression Profiling | 3 | 2019 | 1683 | 0.050 |
Why?
| Biological Transport | 2 | 2015 | 403 | 0.050 |
Why?
| Uric Acid | 1 | 2005 | 161 | 0.050 |
Why?
| Cholesterol | 1 | 2005 | 412 | 0.050 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.050 |
Why?
| Chromosomes | 1 | 2024 | 100 | 0.050 |
Why?
| Proteins | 1 | 2009 | 941 | 0.050 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2004 | 33 | 0.050 |
Why?
| Calcineurin Inhibitors | 1 | 2003 | 68 | 0.050 |
Why?
| Wounds and Injuries | 1 | 2010 | 710 | 0.050 |
Why?
| Injections, Intravenous | 1 | 2003 | 202 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2024 | 1416 | 0.050 |
Why?
| RNA, Small Interfering | 2 | 2016 | 591 | 0.050 |
Why?
| Drug Carriers | 1 | 2024 | 119 | 0.050 |
Why?
| Cardiac Output | 1 | 2003 | 156 | 0.050 |
Why?
| Coronary Circulation | 1 | 2003 | 138 | 0.050 |
Why?
| Gliosis | 1 | 2023 | 28 | 0.050 |
Why?
| Acetylcysteine | 1 | 2004 | 146 | 0.050 |
Why?
| Mitochondria, Liver | 1 | 2003 | 74 | 0.050 |
Why?
| Tyrosine | 1 | 2023 | 222 | 0.050 |
Why?
| Liposomes | 1 | 2024 | 171 | 0.050 |
Why?
| Necrosis | 3 | 2010 | 231 | 0.050 |
Why?
| Mitochondria, Heart | 1 | 2003 | 94 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| Isoflurane | 1 | 2002 | 27 | 0.050 |
Why?
| Anesthetics, Intravenous | 1 | 2002 | 44 | 0.050 |
Why?
| Models, Cardiovascular | 1 | 2003 | 191 | 0.050 |
Why?
| Child | 4 | 2024 | 20768 | 0.050 |
Why?
| Rupture | 1 | 2022 | 91 | 0.050 |
Why?
| Adenocarcinoma | 1 | 2009 | 891 | 0.050 |
Why?
| Reperfusion | 1 | 2002 | 38 | 0.050 |
Why?
| Anterior Cruciate Ligament | 1 | 2022 | 80 | 0.050 |
Why?
| Oxaloacetic Acid | 1 | 2001 | 3 | 0.050 |
Why?
| Tumor Burden | 2 | 2014 | 286 | 0.050 |
Why?
| AMP-Activated Protein Kinases | 2 | 2013 | 190 | 0.050 |
Why?
| Aspartic Acid | 1 | 2001 | 80 | 0.050 |
Why?
| Succinic Acid | 2 | 2013 | 38 | 0.050 |
Why?
| Middle Aged | 6 | 2016 | 31049 | 0.040 |
Why?
| Tibia | 1 | 2022 | 170 | 0.040 |
Why?
| RNA Polymerase II | 1 | 2024 | 317 | 0.040 |
Why?
| Teratoma | 1 | 2022 | 103 | 0.040 |
Why?
| Microsomes, Liver | 1 | 2001 | 87 | 0.040 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 84 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 441 | 0.040 |
Why?
| Coronary Vessels | 1 | 2002 | 239 | 0.040 |
Why?
| Random Allocation | 3 | 2006 | 346 | 0.040 |
Why?
| Drug Therapy, Combination | 3 | 2016 | 1040 | 0.040 |
Why?
| gamma-Aminobutyric Acid | 1 | 2001 | 168 | 0.040 |
Why?
| Brain Stem Neoplasms | 1 | 2020 | 81 | 0.040 |
Why?
| Heart Failure | 1 | 2013 | 2129 | 0.040 |
Why?
| Ligands | 2 | 2012 | 620 | 0.040 |
Why?
| Hematinics | 1 | 2019 | 20 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 115 | 0.040 |
Why?
| Pulmonary Alveoli | 1 | 2002 | 400 | 0.040 |
Why?
| Phenotype | 3 | 2016 | 3071 | 0.040 |
Why?
| Tunica Intima | 1 | 2000 | 84 | 0.040 |
Why?
| Pregnancy Complications | 1 | 2004 | 493 | 0.040 |
Why?
| Cell Movement | 2 | 2015 | 944 | 0.040 |
Why?
| Sheep, Domestic | 1 | 2019 | 34 | 0.040 |
Why?
| Fluorescent Antibody Technique | 2 | 2013 | 375 | 0.040 |
Why?
| Enzyme Activation | 2 | 2013 | 812 | 0.040 |
Why?
| Knee Joint | 1 | 2022 | 372 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 350 | 0.040 |
Why?
| Mouth Mucosa | 1 | 2019 | 88 | 0.040 |
Why?
| Survival Analysis | 2 | 2016 | 1268 | 0.040 |
Why?
| Radiology, Interventional | 1 | 2019 | 30 | 0.040 |
Why?
| Drug Administration Schedule | 2 | 2013 | 767 | 0.040 |
Why?
| Transplantation, Homologous | 1 | 2000 | 400 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2000 | 423 | 0.040 |
Why?
| Mifepristone | 1 | 2018 | 64 | 0.040 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2018 | 17 | 0.040 |
Why?
| Salivary Glands | 1 | 2018 | 29 | 0.040 |
Why?
| Amino Acids | 1 | 2002 | 486 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 204 | 0.040 |
Why?
| Lysine | 1 | 2020 | 286 | 0.040 |
Why?
| Phantoms, Imaging | 1 | 2019 | 137 | 0.040 |
Why?
| Breast | 1 | 2019 | 152 | 0.040 |
Why?
| NF-kappa B | 2 | 2013 | 663 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2010 | 2340 | 0.040 |
Why?
| Citric Acid Cycle | 1 | 1997 | 54 | 0.040 |
Why?
| Immunohistochemistry | 2 | 2012 | 1678 | 0.040 |
Why?
| Cell Size | 1 | 1997 | 87 | 0.040 |
Why?
| Weight Gain | 1 | 2001 | 509 | 0.040 |
Why?
| Digoxin | 1 | 2017 | 27 | 0.040 |
Why?
| Robotics | 1 | 2019 | 93 | 0.030 |
Why?
| Pentose Phosphate Pathway | 1 | 2017 | 50 | 0.030 |
Why?
| Aorta | 1 | 2000 | 408 | 0.030 |
Why?
| Cytosol | 1 | 1997 | 219 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2018 | 239 | 0.030 |
Why?
| Cysteine | 1 | 2018 | 195 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 70 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2019 | 252 | 0.030 |
Why?
| Benzothiazoles | 1 | 2016 | 32 | 0.030 |
Why?
| Rabbits | 1 | 2018 | 777 | 0.030 |
Why?
| Hydrazines | 1 | 2016 | 34 | 0.030 |
Why?
| Lymph Nodes | 1 | 2019 | 470 | 0.030 |
Why?
| Heat Shock Transcription Factors | 2 | 2006 | 19 | 0.030 |
Why?
| Adventitia | 1 | 2016 | 43 | 0.030 |
Why?
| Membrane Lipids | 1 | 1996 | 91 | 0.030 |
Why?
| Phenylurea Compounds | 1 | 2016 | 88 | 0.030 |
Why?
| Carbon | 1 | 2017 | 204 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 2018 | 455 | 0.030 |
Why?
| Gestational Age | 1 | 2019 | 874 | 0.030 |
Why?
| Fatty Acid Transport Proteins | 1 | 2015 | 19 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2015 | 32 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2016 | 234 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 616 | 0.030 |
Why?
| Animals, Newborn | 1 | 1997 | 834 | 0.030 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 45 | 0.030 |
Why?
| Stem Cell Niche | 1 | 2015 | 53 | 0.030 |
Why?
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| Lipoprotein Lipase | 1 | 2015 | 59 | 0.030 |
Why?
| Sodium Hydroxide | 1 | 2014 | 8 | 0.030 |
Why?
| Risk Factors | 1 | 2009 | 9740 | 0.030 |
Why?
| Precision Medicine | 1 | 2019 | 386 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 67 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2020 | 954 | 0.030 |
Why?
| Radiopharmaceuticals | 1 | 2015 | 166 | 0.030 |
Why?
| Half-Life | 1 | 2014 | 162 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2015 | 316 | 0.030 |
Why?
| Pyrroles | 1 | 2015 | 201 | 0.030 |
Why?
| Recovery of Function | 1 | 2018 | 641 | 0.030 |
Why?
| Bone Marrow | 1 | 2015 | 271 | 0.030 |
Why?
| Superoxides | 1 | 2014 | 201 | 0.030 |
Why?
| Software | 1 | 2019 | 606 | 0.030 |
Why?
| Maze Learning | 1 | 2014 | 104 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2015 | 481 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2014 | 182 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2014 | 297 | 0.030 |
Why?
| Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
| beta-Galactosidase | 1 | 2013 | 77 | 0.030 |
Why?
| Breeding | 1 | 2013 | 62 | 0.030 |
Why?
| Mice, Inbred A | 1 | 2013 | 48 | 0.030 |
Why?
| Tissue Donors | 2 | 2010 | 391 | 0.030 |
Why?
| Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| Particle Size | 1 | 2014 | 351 | 0.030 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2013 | 67 | 0.030 |
Why?
| Somatomedins | 1 | 2013 | 28 | 0.030 |
Why?
| Staining and Labeling | 1 | 2013 | 141 | 0.030 |
Why?
| Vacuoles | 1 | 2013 | 36 | 0.030 |
Why?
| Catalysis | 1 | 2014 | 307 | 0.030 |
Why?
| Risk Assessment | 1 | 2002 | 3231 | 0.030 |
Why?
| Cell Shape | 1 | 2013 | 54 | 0.030 |
Why?
| Hyperplasia | 1 | 2013 | 171 | 0.030 |
Why?
| Mitogens | 1 | 2013 | 59 | 0.030 |
Why?
| RNA Interference | 1 | 2014 | 449 | 0.030 |
Why?
| Keratins | 1 | 2013 | 175 | 0.030 |
Why?
| RNA, Messenger | 2 | 2013 | 2699 | 0.030 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 81 | 0.030 |
Why?
| Glucose Transporter Type 4 | 1 | 2012 | 39 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2013 | 212 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 874 | 0.030 |
Why?
| Integrases | 1 | 2013 | 119 | 0.030 |
Why?
| Adenoviridae | 1 | 2013 | 192 | 0.030 |
Why?
| Carcinogens | 1 | 2013 | 110 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2013 | 192 | 0.020 |
Why?
| Neoplasm Grading | 1 | 2013 | 282 | 0.020 |
Why?
| Epidermal Growth Factor | 1 | 2013 | 169 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2014 | 247 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 169 | 0.020 |
Why?
| Estradiol | 1 | 2015 | 493 | 0.020 |
Why?
| RNA, Untranslated | 1 | 2013 | 117 | 0.020 |
Why?
| Long-Term Potentiation | 1 | 2014 | 196 | 0.020 |
Why?
| Molecular Chaperones | 1 | 2013 | 182 | 0.020 |
Why?
| Colorado | 1 | 2022 | 4402 | 0.020 |
Why?
| Mice, Inbred MRL lpr | 1 | 2011 | 38 | 0.020 |
Why?
| Decision Making | 1 | 2019 | 848 | 0.020 |
Why?
| Self Administration | 1 | 2012 | 120 | 0.020 |
Why?
| Sucrose | 1 | 2012 | 99 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2013 | 311 | 0.020 |
Why?
| beta Catenin | 1 | 2013 | 225 | 0.020 |
Why?
| Bortezomib | 1 | 2011 | 45 | 0.020 |
Why?
| Gene Regulatory Networks | 1 | 2013 | 280 | 0.020 |
Why?
| Kidney Glomerulus | 1 | 2011 | 109 | 0.020 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 209 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 755 | 0.020 |
Why?
| Nestin | 1 | 2010 | 19 | 0.020 |
Why?
| Adenine | 1 | 2013 | 256 | 0.020 |
Why?
| Intermediate Filament Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| Urethane | 1 | 2010 | 41 | 0.020 |
Why?
| Fatigue | 1 | 2013 | 316 | 0.020 |
Why?
| Neutrophils | 2 | 2006 | 1207 | 0.020 |
Why?
| Receptors, Complement 3d | 1 | 2011 | 141 | 0.020 |
Why?
| Protein Biosynthesis | 1 | 2013 | 405 | 0.020 |
Why?
| Immunoblotting | 1 | 2011 | 305 | 0.020 |
Why?
| Mesenteric Arteries | 1 | 2010 | 17 | 0.020 |
Why?
| HT29 Cells | 1 | 2010 | 36 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2011 | 148 | 0.020 |
Why?
| Cluster Analysis | 1 | 2011 | 480 | 0.020 |
Why?
| Kidney Function Tests | 1 | 2010 | 152 | 0.020 |
Why?
| Hydrogen | 1 | 2010 | 65 | 0.020 |
Why?
| Caspase 3 | 1 | 2011 | 245 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 108 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 140 | 0.020 |
Why?
| Limit of Detection | 1 | 2009 | 82 | 0.020 |
Why?
| Constriction, Pathologic | 1 | 2010 | 226 | 0.020 |
Why?
| Transplantation Conditioning | 1 | 2010 | 166 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2013 | 7037 | 0.020 |
Why?
| Citrates | 1 | 2009 | 42 | 0.020 |
Why?
| Portal Vein | 1 | 2010 | 108 | 0.020 |
Why?
| Gene Deletion | 1 | 2010 | 380 | 0.020 |
Why?
| STAT3 Transcription Factor | 1 | 2010 | 194 | 0.020 |
Why?
| Celecoxib | 1 | 2008 | 39 | 0.020 |
Why?
| Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2010 | 399 | 0.020 |
Why?
| Cell Cycle | 1 | 2011 | 588 | 0.020 |
Why?
| Free Radicals | 1 | 2009 | 105 | 0.020 |
Why?
| Bronchoscopy | 2 | 2000 | 215 | 0.020 |
Why?
| Hippocampus | 1 | 2014 | 870 | 0.020 |
Why?
| Dura Mater | 1 | 2008 | 30 | 0.020 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2008 | 44 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2009 | 190 | 0.020 |
Why?
| Mammary Neoplasms, Animal | 1 | 2008 | 30 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1833 | 0.020 |
Why?
| Craniotomy | 1 | 2008 | 67 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 636 | 0.020 |
Why?
| Drug Discovery | 1 | 2009 | 130 | 0.020 |
Why?
| Pressure | 1 | 2008 | 237 | 0.020 |
Why?
| Ethanol | 1 | 2012 | 589 | 0.020 |
Why?
| United States | 1 | 2024 | 13825 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2010 | 529 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2010 | 569 | 0.020 |
Why?
| Hypoglycemic Agents | 1 | 2015 | 1220 | 0.020 |
Why?
| Carcinoma | 1 | 2008 | 214 | 0.020 |
Why?
| Aspartate Aminotransferases | 1 | 2006 | 88 | 0.020 |
Why?
| Peroxidase | 1 | 2006 | 174 | 0.020 |
Why?
| Risk | 1 | 2008 | 851 | 0.020 |
Why?
| Child, Preschool | 1 | 2020 | 10456 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2006 | 153 | 0.020 |
Why?
| Organ Size | 1 | 2006 | 445 | 0.020 |
Why?
| Membrane Transport Proteins | 1 | 2006 | 149 | 0.020 |
Why?
| Case-Control Studies | 1 | 2013 | 3372 | 0.020 |
Why?
| HSP27 Heat-Shock Proteins | 1 | 2005 | 13 | 0.020 |
Why?
| Pilot Projects | 1 | 2010 | 1583 | 0.020 |
Why?
| Quercetin | 1 | 2005 | 10 | 0.010 |
Why?
| Intensive Care Units | 1 | 2010 | 735 | 0.010 |
Why?
| Cerebral Cortex | 1 | 2008 | 436 | 0.010 |
Why?
| Intestinal Mucosa | 1 | 2010 | 589 | 0.010 |
Why?
| Cytokines | 1 | 2013 | 2012 | 0.010 |
Why?
| Dietary Fats | 1 | 2006 | 301 | 0.010 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 757 | 0.010 |
Why?
| Computational Biology | 1 | 2009 | 596 | 0.010 |
Why?
| Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| Raffinose | 1 | 2003 | 23 | 0.010 |
Why?
| Allopurinol | 1 | 2003 | 62 | 0.010 |
Why?
| Organ Preservation Solutions | 1 | 2003 | 45 | 0.010 |
Why?
| Transcriptional Activation | 1 | 2005 | 367 | 0.010 |
Why?
| Cell Membrane | 1 | 2006 | 732 | 0.010 |
Why?
| Protein Binding | 1 | 2009 | 2120 | 0.010 |
Why?
| Chromatography, Gas | 1 | 2002 | 32 | 0.010 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 235 | 0.010 |
Why?
| Adenosine | 1 | 2003 | 227 | 0.010 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 179 | 0.010 |
Why?
| Preoperative Care | 1 | 2004 | 338 | 0.010 |
Why?
| Trans-Activators | 1 | 2004 | 389 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1463 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2005 | 877 | 0.010 |
Why?
| Automation | 1 | 2000 | 81 | 0.010 |
Why?
| Microchemistry | 1 | 2000 | 20 | 0.010 |
Why?
| Calibration | 1 | 2000 | 140 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| Pain Measurement | 1 | 2002 | 506 | 0.010 |
Why?
| Emulsions | 1 | 2000 | 51 | 0.010 |
Why?
| Autopsy | 1 | 2000 | 90 | 0.010 |
Why?
| Blood | 1 | 2000 | 105 | 0.010 |
Why?
| Postoperative Period | 1 | 2000 | 329 | 0.010 |
Why?
| Prospective Studies | 1 | 2010 | 7117 | 0.010 |
Why?
| Chronic Disease | 1 | 2004 | 1714 | 0.010 |
Why?
| Immune Tolerance | 1 | 2000 | 355 | 0.010 |
Why?
| Regression Analysis | 1 | 2000 | 992 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2000 | 648 | 0.010 |
Why?
| Biopsy | 1 | 2000 | 1084 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2000 | 1833 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|